HiberCell

Hiber Cell

Biotechnology, 619 W 54th St Fl 8, New York, 10019, United States, 51-200 Employees

hibercell.com

  • LinkedIn

phone no Phone Number: 65********

Who is HIBERCELL

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity....

Read More

map
  • 619 W 54th St Fl 8, New York, New York, 10019, United States Headquarters: 619 W 54th St Fl 8, New York, New York, 10019, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from HIBERCELL

HiberCell Org Chart and Mapping

Employees

Alexander Conte

Senior Business Development Manager

Weiyu Zhang

Senior Scientist, Preclinical Pharmacology

Beth Johnson

Executive Assistant & Officer Manager

Jeremy Drees

Associate Director, Translational Immunology

Nicole Meinhardt

Clinical Project Manager

Nick Niles

Director Clinical Operations

Michael Danielson

Executive Director Head of Cmc

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding HiberCell

Answer: HiberCell's headquarters are located at 619 W 54th St Fl 8, New York, 10019, United States

Answer: HiberCell's phone number is 65********

Answer: HiberCell's official website is https://hibercell.com

Answer: HiberCell's revenue is $1 Million to $5 Million

Answer: HiberCell's SIC: 8731

Answer: HiberCell's NAICS: 541714

Answer: HiberCell has 51-200 employees

Answer: HiberCell is in Biotechnology

Answer: HiberCell contact info: Phone number: 65******** Website: https://hibercell.com

Answer: HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access